AstraZeneca and Merck PARP Inhibitor Lynparza
The AstraZeneca (AZN) and Merck (MRK) PARP inhibitor Lynparza (olaparib) has been granted approval in Europe for first-line maintenance monotherapy . . .
This content is for paid subscribers.
Today’s Highlights
June 19, 2019
